RBC Capital Downgrades PTC Therapeutics (PTCT) to Sector Perform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to RBC Capital Downgrades PTC Therapeutics (PTCT) to Sector Perform

PTC Receives Refuse to File Letter from FDA for Translarna™ (ataluren)

February 23, 2016 8:14 AM EST

SOUTH PLAINFIELD, N.J., Feb. 23, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it received yesterday evening a Refuse to File letter from the United States Food and Drug Administration (FDA) regarding PTC's New Drug Application (NDA) for Translarna (ataluren), an oral, first-in-class, protein restoration therapy for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).

The FDA states in the Refuse to File letter that the application was not sufficiently complete to permit a substantive review.  PTC first learned of the Refuse to File decision via... More